Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting
|
|
- Erik Hodge
- 5 years ago
- Views:
Transcription
1 March 2011 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair), Keith Lyke R.Ph., Dennis Chapron, M.S., Richard Gannon, Pharm.D., Bhupesh Mangla, M.D., Ram Illindala, M.D., Charles Caley, Pharm.D. Ex-Officio Non-Voting Member Present: Heather L. Kissinger, Pharm. D. (HID DUR Board Coordinator and Secretary), James Zakszewski, R.Ph. (DSS), Ellen Arce, R.Ph. (HP) Guests: Wendy Pollinger (Eli Lilly), Adam Denman (GlaxoSmithKline) INTRODUCTORY BUSINESS Ken Fisher called the meeting to order at 6:45 p.m. OLD BUSINESS A. Previous Meeting Minutes It was requested to change the fourth bullet point from the bottom on page two, move and so the point reads Ken Fisher and Bhupesh Mangla It was requested to correct the spelling of linked on the sixth bullet point on page three. It was requested to correct the spelling of oxcarbazepine on the fourteenth bullet point on page three. It was requested to change indiacted to indicated on the fourth bullet point on page four. It was requested to change note to noted on the tenth bullet point on page four. I was requested to change that is to if on the thirteenth bullet point on page four. It was requested to change generic to genetic on the fifteenth bullet point on page four. The December 2010 DUR Board meeting minutes were approved with changes by all members. B. Follow-Up from Previous Meeting The Board reviewed section 3 titled Follow-up from the September Follow-up 1, a request was made for the Pharmacy team at HP to review the Drug-Drug and Therapeutic Duplication ProDUR Alerts. 1
2 March 2011 Minutes Ellen Arce stated this request would be worked on and followed up with during the June 2011 DUR Board meeting. Follow-up 2, a request was made to know why prenatal vitamins were the top drug class causing the pregnancy precautions alert to set (found on page 38 of the FFY 2009 CMS Report). Ellen Arce stated this request would be worked on and followed up with during the June 2011 DUR Board meeting. Follow-up 3, a request was made to know how many claims for Suboxone were processed for more than 16mg per day during a 3 month period in time. Heather Kissinger stated that from 5/20/2010 through 8/20/2010 there were 4390 claims for Suboxone 8 mg products where patients were receiving more than 16 mg per day. The claims for doses greater than 16 mg/day totaled $1,312, during the 3 month period. Bhupesh asked to know what percentage of patients were taking more than the recommended 16 mg per day. Heather said she would report back to the Board. Jim Zakszewski asked what the normal duration is for suboxone therapy and Dennis Chapron asked the difference between suboxone treatment and methadone when treating opioid dependence. Rich Gannon stated that some patients may be on Suboxone for extended periods of time and the difference between suboxone and methadone treatments may be that suboxone is used more in private practice settings where methadone is given out at dispensaries. He also added that a new patch form of buprenorphine just came on to the market, Butrans, but the dose is very low. Rich also stated that doses greater than 16 mg/day of suboxone may be necessary in some patients. Charlie Caley stated that when treating substance abuse no available treatment guarantees relapse prevention and sustained psychological treatment programs are necessary to help patients with their addictions. Ram Illindala stated that reimbursement for psychiatric counseling is so low; physicians tend to not perform the counseling. Bhupesh Mangla stated that support for better reimbursement and counseling will offer a better treatment environment for patients and the patients may be more receptive. Jim Zakszewski agreed. 2
3 March 2011 Minutes Follow-up 4, the board requested the polypharmacy intervention target patients who consecutively received 15 or more medications in a single month over the course of 3 months. Heather Kissinger stated the intervention is set to be performed after the March 2011 meeting and in October 3010 patients received 15 or more medications, in November 3167 patients received 15 or more medications, and in December 3078 patients received 15 or more medications. The polypharmacy intervention will target approximately 3,000 patients over the course of 3 months. Follow-up 5, a request was made to pair the polypharmacy intervention scheduled to follow the March 2011 with a newsletter about medication use in the elderly, the Beers List, and also include a small section recapping the polypharmacy newsletter sent in June Heather Kissinger stated the newsletter could be found in section eight of the Board meeting packets and would be reviewed later during the meeting. Follow-up 6, a request was made to know if on the patient profiles physicians receive for targeted interventions, are other physician NPIs displayed on the profile. Heather Kissinger stated the other prescriber NPIs are listed on the patient profile that is sent to a physician for a targeted intervention. Follow up 7, a request was made to make the following changes to the fentanyl PA form: o Add (18 years or greater for Onsolis) next to requirement number 2 o Add a sixth requirement for use that states patient may not receive greater than 4 doses per day o Change the PA help desk phone number to the HP PA help desk Once the changes are made the PA form will be send to DSS. Heather stated Abstral was also added to the PA form, Abstral is the newest fentanyl citrate product released to the market a few months ago. Heather passed out the updated PA form along with the notification letter to providers informing them of the PA implementation. The Board requested to bold and underline current in the section of the PA form where it asks the provider to list all current opioid therapy and duration of use. It was also requested to add an additional line for the providers to list the current opioid therapies their patient is receiving. Heather stated the requested changes would be made to the form. 3
4 March 2011 Minutes Follow up 8, a request was made to know if beta blockers with alpha-1 blocking potential (labetalol and carvedilol) pose a therapeutic duplication risk with alpha-1 blocking drugs. Heather directed the Board to review attachment B; mechanism of action information and drugdrug interaction. The drug information appears to list the interaction as moderate; however, it does not state specifically that the interaction between beta blockers with alpha blocking potential when used with alpha blockers is due to the additive alpha blocking potential. Follow up 9, a request was made to know all criteria turned on for CT with a Problem code Drug contraindicated in pregnancy. Heather Kissinger directed the Board to review attachment C. The Board requested to have the title of Problem Code 108 changed to read Drugs cautioned or contraindicated in pregnancy. It was also requested to delete any criteria under Problem Code 108 that was pregnancy category B or C. Jim requested the other drugs that cause fetal hydantoin syndrome (phenytoin, primidone, valproate, carbamazepine, and trimethadione) be added to criteria 461. Charlie asked to also add oxcarbamazepine to the alert message. Heather stated she would complete the requests. Jim questioned if criteria 431, regarding nicotine replacement therapy use in pregnancy, be removed from the criteria list due to the recent change in coverage for all smoking cessation products for Medicaid patients. The Board pointed out the criteria states that nicotine is FDA pregnancy category D and is not recommended for use in pregnancy. They did not recommend the removal of criteria 431. Dennis stated that Topamax was recently changed from category C to category D when used in pregnancy. Heather stated she would check with the criteria manager, Pam DeRuiter, to have the current criteria changed. C. Criteria Trend Summary Heather Kissinger stated that section 4 is the criteria trend summary, the purpose of this report is to review criteria previously reviewed 6 months after intervention letters are mailed to evaluate if the intervention had an impact on the population. For the Adult reviews: 4
5 March 2011 Minutes Criteria 1598 (Alert Message: Nonadherence to the prescribed antihypertensive regimen may result in poor blood pressure control, disease progression and additional health care costs) had 1070 hits in April 2010 and increased to 1445 hits in October Criteria 1073 (Alert message: Therapeutic duplication of antihistamine agents may be occurring) had 886 hits in May 2010 and decreased to 183 hits in November Criteria 1603, (Therapeutic duplication of salmeterol products may be occurring. Large doses of salmeterol have been associated with increases in heart rate, significant reduction in diastolic pressure, and prolongation of QTc interval which may potentially produce life-threatening arrhythmias.) had 164 hits in May 2010 and decreased to 76 hits in November Criteria 1679, (Alert message: Therapeutic duplication of intranasal steroids may be occurring) had 52 hit in May 2010 and decreased to 29 hits in November Criteria 809, (Alert message: The profile history indicates that the patient has a diagnosis of osteoporosis and is receiving sedative/anxiolytic therapy. The use of sedatives and/or anxiolytic therapy may result in increased sedation. In patients with osteoporosis this may increase the risk of falls and fractures. This patient may be at risk since they are not currently receiving treatment for osteoporosis) had 237 hit in June 2010 and decreased to 217 hits in December Criteria 810, (Alert message: The profile history indicates that the patient has a diagnosis of osteoporosis and is receiving narcotic therapy. The use of narcotic therapy may result in increased sedation. In patients with osteoporosis this may increase the risk of falls and fractures. This patient may be particularly at risk since they are not currently receiving treatment for osteoporosis) had 106 hits in June 2010 and decreased to 70 hits in December Criteria 811, (Alert message: The profile history indicates that the patient has a diagnosis of osteoporosis and is receiving corticosteroid therapy. Corticosteroid therapy in patients with osteoporosis may increase the risk of fractures due to decreased bone density associated with corticosteroid use. This patient may be particularly at risk since they are not currently receiving treatment for osteoporosis) had 46 hits in June 2010 and decreased to 32 hits in December Criteria 1262, (Alert message: The profile history indicates that the patient has a diagnosis of osteoporosis and is receiving sedative/anxiolytic therapy. The use of sedative and/or anxiolytic therapy may cause dizziness and grogginess which can put the patient at increased risk for fallrelated injuries) had 419 hits in June 2010 and decreased to 363 hits in December Criteria 1264, (Alert message: The profile history indicates that the patient has a diagnosis of osteoporosis and is receiving corticosteroid therapy. Corticosteroid therapy may increase the 5
6 March 2011 Minutes risk of fractures in patients with osteoporosis due to decreased bone density associated with corticosteroid use) had 84 hits in June 2010 and decreased to 69 hits in December Criteria 113, (Alert message: Diuretic agents may cause or exacerbate hyperuricemia) had 472 hits in July 2010 and decreased to 228 hits in January Criteria 948, (Alert message: Antibiotics may decrease the effectiveness of oral and transdermal contraceptives by altering intestinal flora and/or estrogen plasma concentrations. When used to prevent pregnancy, it is recommended that additional contraceptive precautions be used for the entire duration of therapy and for 7 days after a short course of any antibiotic) had 96 hits in July 2010 and decreased to 77 hits in January Criteria 797, (Alert message: Certain medications can cause induction of liver enzymes and speed the metabolism of oral, transdermal and vaginal contraceptives. A partial list includes: barbiturates, phenytoin, carbamazepine, felbamate, oxcarbazine, and St John's Wort. Use caution when using these drugs concomitantly as they may decrease effectiveness of the contraceptives. An alternative method of contraception may be necessary) had 103 hits in July 2010 and decreased to 62 hits in January Criteria 2959, (Alert message: Anticholinergic agents may cause or worsen dry eye. A patient receiving an anticholinergic drug concurrently with Restasis (ophthalmic cyclosporine) may not experience the optimal therapeutic effect of the ophthalmic cyclosporine) had 48 hits in July 2010 and decreased to 37 hits in January Criteria 619, (Alert message: Therapeutic duplication of HMG CoA reductase inhibitors may be occurring) had 496 hits in August 2010 and decreased to 281 hits in February Criteria 631, (Alert message: Therapeutic duplication of beta-blockers may be occurring) had 523 hits in August 2010 and decreased to 392 hits in February For the Pediatric Reviews: Problem Code 186 (Inappropriate Pediatric Therapy) had 1804 hits in July and August and decreased to 1726 hits in February Rich asked if HID performed the pediatric intervention warning physicians of metabolic syndrome when using atypical antipsychotics. Heather stated that intervention was performed in November 2010, December 2010, and January
7 Retrospective Drug Utilization Review March 2011 Minutes A. Program Summary Review The Board reviewed the program summary review for 3 rd and 4 th quarter 2010 in section 5. Heather Kissinger stated that during 3 rd QTR 2010 prescription claims cost, the number of prescriptions filled, the total number of unique recipients, and the cost of recipient per month decreased when compared to the 2 nd quarter The cost paid per prescription increased when compared to the 2 nd quarter Charlie asked where Connecticut fell in comparison with other states with regard to per member per month cost. Ellen said that information is published by Kaiser Permanente. Heather Kissinger stated that during the 4 th QTR 2010 the number of prescriptions filled decreased, but prescription claims cost, total number of unique recipients, the cost of recipient per month, and the cost paid per prescription all increased when compared to the 3 rd QTR. Dennis stated that $160,000,000 per quarter was a lot to spend on prescriptions alone. He asked if this was taken into consideration when budgets were discussed. Both Jim and Ellen responded and pointed out that these figures don t take into consideration the amount the State receives from drug rebate. Ellen stated that the State received about $60,000,000 per quarter in rebate dollars. Jim stated that all drugs are covered under Medicaid and on the Preferred Drug List if they are subject to federal rebate. He invited the Board members to the next P&T meeting to show how drugs are added or removed from the PDL. Ken asked if Heather would send an informing the members of the next P&T meeting as the date gets closer. B. Intervention Activity Report The Board reviewed the Intervention Activity report for 3 rd and 4 th quarter 2010 in section 6. It was stated that the Intervention Activity Report is a monthly summary of the distribution of letters mailed to prescribers and also summarizes the main criteria that were reviewed each month. In July 2010, 2969 letters were sent. The main interventions reviewed for the adult population were: 7
8 March 2011 Minutes Therapeutic duplication of HMG CoA reductase inhibitors may be occurring.( 322 letters) Therapeutic duplication of beta-blockers may be occurring. (283 letters) Lock-in criteria (830 letters) The main intervention reviewed for the pediatric population was: Inappropriate Pediatric Therapy (350 letters) In August 2010, 2692 letters were sent. The main interventions reviewed for the adult population was: The accredited medical literature does not suggest that the COX-2s have an efficacy advantage over the non-selective NSAIDS. Non-selective NSAIDS should remain first line therapy. Cost effectively, COX-2 inhibitors should be reserved for patients in which bleeding is a readily apparent concern and for patients who have demonstrated an inability to tolerate other NSAIDS due to gastrointestinal bleeding or ulceration. COX-2s and NSAIDS should not be used concurrently. The hemorrhagic protective benefit is negated when even small doses of nonselective NSAIDS are utilized. (276 letters) Lock-in criteria (755 letters) The main interventions reviewed for the pediatric population were: Additive Sedation (57 letters) Anticonvulsant Interaction (46 letters) Overutilization (193 letters) Inappropriate Dosing Regimen (215 letters) In September 2010, 2800 letters were sent. The main intervention reviewed for the adult population was: Underutilization of Antidepressants (580 letters) Lock-in criteria (764 letters) The main intervention reviewed for the pediatric population was: The patient is under the age of 18 with a diagnosis of ADHD and is receiving an atypical antipsychotic with no evidence, in their diagnostic history, of a FDA approved indication for use. Atypical antipsychotics have not been shown to be safe and effective for the treatment of ADHD. These agents have significant adverse effects which can be more prevalent and severe in pediatric patients. (491 letters) In October 2010, 2437 letters were sent. The main intervention reviewed for the adult population was: 8
9 March 2011 Minutes Therapeutic duplication of benzodiazepine therapy may be occurring. (306 letters) Lock-in criteria (1152 letters) The main intervention reviewed for the pediatric population was: The effects of prolonged use of atypical antipsychotics in pediatric patients are unknown. Preliminary evidence suggests that pediatric patients experience more prevalent and severe adverse effects than those reported in adults (e.g., weight gain, extrapyramidal side effects, and insulin resistance). If therapy with these agents is clinically necessary use the lowest effective dose and observe patients closely for adverse events. If adverse effects cannot be controlled consider switching, if clinically possible, to a SGA with a more favorable adverse effect profile. (480 letters) In November 2010, 2031 letters were sent. The main intervention reviewed for the adult population was: Therapeutic duplication of benzodiazepine therapy may be occurring. (384 letters) Lock-in criteria (672 letters) The main intervention reviewed for the pediatric population was: The effects of prolonged use of atypical antipsychotics in pediatric patients are unknown. Preliminary evidence suggests that pediatric patients experience more prevalent and severe adverse effects than those reported in adults (e.g., weight gain, extrapyramidal side effects, and insulin resistance). If therapy with these agents is clinically necessary use the lowest effective dose and observe patients closely for adverse events. If adverse effects cannot be controlled consider switching, if clinically possible, to a SGA with a more favorable adverse effect profile. (472 letters) In December 2010, 3064 letters were sent. The main intervention reviewed for the adult population was: Therapeutic duplication of benzodiazepine therapy may be occurring. (601 letters) Lock-in criteria (723 letters) The main intervention reviewed for the pediatric population was: The effects of prolonged use of atypical antipsychotics in pediatric patients are unknown. Preliminary evidence suggests that pediatric patients experience more prevalent and severe adverse effects than those reported in adults (e.g., weight gain, extrapyramidal side effects, and insulin resistance). If therapy with these agents is clinically necessary use the lowest effective dose and observe patients closely for adverse events. If adverse effects cannot be 9
10 March 2011 Minutes controlled consider switching, if clinically possible, to a SGA with a more favorable adverse effect profile. (477 letters) C. RetroDUR Criteria New Criteria Criteria 1, Lurasidone /Overutilization was approved as written by the Board. Criteria 2, Lurasidone /Moderate & Severe renal and hepatic impairment was approved as written by the Board. Criteria 3, Lurasidone /Non-Adherence was approved as written by the Board. Criteria 4, Lurasidone /Strong CYP 3A4 Inhibitors was approved as written by the Board. Criteria 5, Lurasidone / Strong CYP 3A4 Inducers was approved as written by the Board. Criteria 6, Lurasidone/ Moderate 3A4 Inhibitors was approved as written by the Board. Criteria 7, Lurasidone/ Therapeutic Appropriateness was approved as written by the Board. Criteria 8, Kapvay/ Overuse was approved as written by the Board. Criteria 9, Kapvay/ Non-adherence was approved as written by the Board. Criteria 10, Kapvay /Therapeutic Duplication was approved as written by the Board. Criteria 11, Silenor/ Overuse was approved as written by the Board. D. Newsletter The Board approved the March 2011 DUR Newsletter with the following modifications: o Insert a table on the first page showing the top drugs from the Beers 2003 list currently used by the Medicaid population The Board agreed that the newsletter would be approved once those changes were made. Dennis suggested the next newsletter pertain to top drugs that cause the most emergency room visits. NEW BUSINESS Heather stated Joseph Bordonaro had resigned from the DUR Board and is currently searching for a new member to replace Joe. Ken stated he may have someone who is interested and would Heather the contact. 10
11 March 2011 Minutes Ken reminded the members that the next DUR Board meeting is scheduled for Tuesday June 7, 2011 at 6:30 pm. The meeting was adjourned at 9:15 pm. 11
Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting
March 2015 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair), Keith Lyke R.Ph., Bhupesh Mangla, MD, Richard Gannon, Pharm.D., Charles Caley Pharm.D. BCPP, Ram Illindala, MD, Carol
More informationConnecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting
December 2012 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair), Keith Lyke R.Ph., Dennis Chapron, M.S., Bhupesh Mangla, M.D., Charles Caley, Pharm.D., Ram Illindala, M.D., Richard
More informationConnecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting
September 2018 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair), Keith Lyke, R.Ph., Bhupesh Mangla, MD, Richard Gannon, Pharm.D., Ram Illindala, MD, Dennis Chapron, Pharm.D. Ex Officio
More informationConnecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting
September 2008 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair); Dennis Chapron, M.S.; Richard Gannon, Pharm.D.; Keith Lyke R.Ph., Mike Moore, R.Ph., MPH; Bhupesh Mangla, M.D., Ram
More informationConnecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting
June 2008 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair); Dennis Chapron, M.S.; Richard Gannon, Pharm.D.; Keith Lyke R.Ph., Mike Moore, R.Ph., MPH; Bhupesh Mangla, M.D., Ram Illindala,
More informationConnecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting
March 2018 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair), Keith Lyke, R.Ph., Bhupesh Mangla, MD, Richard Gannon, Pharm.D., Ram Illindala, MD, Dennis Chapron, PharmD., Carol Drufva,
More informationConnecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting
ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair), Keith Lyke R.Ph., Dennis Chapron, M.S., Bhupesh Mangla, M.D., Ram Illindala, M.D., Richard Gannon, Pharm.D., Carol Drufva R.Ph., Angela Moemeka,
More informationConnecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting
ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair), Keith Lyke R.Ph., Dennis Chapron, M.S., Richard Gannon, Pharm.D., Bhupesh Mangla, M.D., Ram Illindala, M.D., Charles Caley, Pharm. D., Angela
More informationCONNECTICUT MEDICAL ASSISTANCE DUR BOARD MEETING MINUTES SUMMARY CMS FFY 2003
CONNECTICUT MEDICAL ASSISTANCE DUR BOARD MEETING MINUTES SUMMARY CMS FFY 2003 DUR BOARD MEMBERSHIP 10/01/2002 to 09/30/2003 Kenneth Fisher, R.Ph. (Chair), Dennis Chapron, M.S., R.Ph., Richard Gannon, PharmD.,
More informationConnecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting
December 2011 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair), Keith Lyke R.Ph., Dennis Chapron, M.S., Richard Gannon, Pharm.D., Bhupesh Mangla, M.D., Ram Illindala, M.D., Angela
More informationIdaho DUR Board Meeting Minutes
Idaho DUR Board Meeting Minutes Date: July 20, 2017 Time: 9am-12:30pm Location: Holiday Inn Boise Airport 2970 West Elder Street, Boise, Idaho, 83705 Moderator: David Agler, M.D. Committee Member Present:
More informationIdaho DUR Board Meeting Minutes
Idaho DUR Board Meeting Minutes Date: Jan. 16, 2014 Time: 9am-1pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Member Present:
More informationAppropriate Use & Safety Edits
Appropriate Use & Safety Edits Envolve Pharmacy Solutions provides a variety of safety edits to promote the use of the right medication, in the right patient, at the right time. These edits are routinely
More informationIdaho DUR Board Meeting Minutes
Date: July 16, 2015 Time: 9am-1:30pm Idaho DUR Board Meeting Minutes Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Member Present:
More informationConnecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting
ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair), Keith Lyke R.Ph., Dennis Chapron, M.S., Richard Gannon, Pharm.D., Bhupesh Mangla, M.D., Ram Illindala, M.D., Charles Caley, Pharm. D., Angela
More informationNews & Views. Antipsychotics on Maryland Medicaid PDL and Coverage of a 30-day Emergency Supply of Atypical Antipsychotics
Maryland Medicaid Pharmacy Program News & Views February 2011 Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy Antipsychotics on Maryland Medicaid PDL and Coverage
More informationIdaho DUR Board Meeting Minutes
Idaho DUR Board Meeting Minutes Date: January 21, 2016 Time: 9am-1:30pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Members
More informationIdaho DUR Board Meeting Minutes. Committee Member Present: Matthew Hyde, Pharm.D., Perry Brown M.D., Paul Cady, Pharm.D., Ryan Heyborne M.D.
Date: February 16, 2017 Time: 9am-12:15pm Idaho DUR Board Meeting Minutes Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Perry Brown, M.D. Committee Member
More informationCurbing Prescription Drug Abuse in Medicaid
Curbing Prescription Drug Abuse in Medicaid Joint Legislative Health Care Oversight Committee October 12, 2010 Dr. Lisa Weeks, BSPharm, PharmD Pharmacy and Ancillary Services Division of Medical Assistance
More informationCLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics
Reference Number: AZ.CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationMedicaid Perspective
Prescription Opioid Fraud and Abuse: Medicaid Perspective Presenter: Gary P. Gilmore, B.S., R.Ph. Director, Analysis & Reporting Office of Clinical Affairs Deputy Director, Pharmacy Program Objectives:
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE September 4, 2015 SUBJECT EFFECTIVE DATE September 9, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Analgesics, Narcotic Long Acting and Analgesics, Narcotic Short
More informationNBPDP Drug Utilization Review Process Update
Bulletin # 802 December 1, 2010 NBPDP Drug Utilization Review Process Update The New Brunswick Prescription Drug Program (NBPDP) employs a Drug Utilization Review (DUR) process which identifies, investigates
More informationDrug Utilization Review Board
DUR Members present DUR members absent MDCH/MMA/MPA present Steven Bernstein, M.D., Chair Carrie Germain, R. Ph, Vice Chair Bob DeYoung, PharmD James Forshee, M.D. Debera Eggleston, M.D. Sahar Swiden,
More informationClinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19
Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE January 6, 2016 SUBJECT EFFECTIVE DATE January 20, 2016 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of COPD Agents Pharmacy Service Leesa M. Allen, Deputy Secretary
More informationFollow-up to Previous Reviews
21 January 2016 1 Follow-up to Previous Reviews Patients Receiving > 1 Long-Acting Opioid Multiple Dosage Forms of Aripiprazole Prescribed Concomitantly Multiple Dosage Forms of Oral Paliperidone Prescribed
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: LA.PPA.12 Effective Date: 02/11 Last Review Date: 01/18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this policy for
More informationIdaho DUR Board Meeting Minutes
Idaho DUR Board Meeting Minutes Date: October 16, 2014 Time: 9am-2pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Member Present:
More informationIOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515)
IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515) 974-3131 -866-626-0216 Brett Faine, Pharm.D. Larry Ambroson, R.Ph. Casey Clor, M.D. Professional Staff: Mark Graber, M.D., FACEP
More informationApril 21, 2010 DURB Meeting Summary
Roll Call Present: Dr. Swee, Ms. Olson, Ms. Martinez- Rodriguez, Dr. Barberio, Dr. Gooen, Dr. Gochfeld, Dr. Lichtbroun Absent: Dr. Moore, Dr. Marcus, Mr. Schafer, Dr. Moynihan, Review of Minutes Pages
More informationFollow-up to Previous Reviews. Multiple Dosage Forms of Aripiprazole Prescribed Concomitantly
15 October 2015 1 Follow-up to Previous Reviews Multiple Dosage Forms of Aripiprazole Prescribed Concomitantly 2 Multiple Dosage Forms of Aripiprazole Prescribed Concomitantly Usual maximum FDA approved
More informationClinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid
Clinical Policy: Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationMichael O Neil, Pharm.D. Professor and Vice-Chair, Department of Pharmacy Practice Drug Diversion, Substance Abuse, and Pain Management Consultant
Michael O Neil, Pharm.D. Professor and Vice-Chair, Department of Pharmacy Practice Drug Diversion, Substance Abuse, and Pain Management Consultant South College School of Pharmacy Knoxville, TN (304) 546-7746
More informationClinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18
Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationIOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road Des Moines, IA (515) Fax
IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road Des Moines, IA 50315 (515) 725-1287 Fax 1-866-626-0216 Bruce Alexander, R.Ph., Pharm.D., BCPP Larry Ambroson, R.Ph. Casey Clor, M.D.
More informationPL CE LIVE February 2011 Forum
February 2011 PL CE LIVE Kristin W. Weitzel, Pharm.D., CDE, FAPhA Associate Editor and Director of Editorial Projects Pharmacist s Letter/Prescriber s Letter Atypical Antipsychotics Atypical Antipsychotics
More informationTips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs. June 5, 2015
Tips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs 1 June 5, 2015 Introductions Mark Steck Pharm.D Independent Consultant, MAXIMUS John J.P. Crouse Vice President, MAXIMUS Market Lead
More informationClinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: 03.01.12 Last Review Date: 02.19 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationSuboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description
More informationDuragesic patch. Duragesic patch (fentanyl patch) Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 6 Last Review Date: March 18, 2016 Duragesic patch Description Duragesic patch (fentanyl
More informationIOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road Des Moines, IA (515) Fax
IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road Des Moines, IA 50315 (515) 974-3131 Fax 1-866-626-0216 Brett Faine, Pharm.D. Larry Ambroson, R.Ph. Casey Clor, M.D. Mark Graber, M.D.,
More informationClinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: 03.01.12 Last Review Date: 02.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationIowa Medicaid Drug Utilization Review Commission Meeting Minutes March 3, 2010
Iowa Medicaid Drug Utilization Review Commission Meeting Minutes March 3, 2010 Attendees: Commission Members Bruce Alexander, R.Ph., Pharm.D., BCPP; Craig Logemann, R.Ph., Pharm.D., BCPS; Sara Schutte-Schenck,
More informationIdaho DUR Board Meeting Minutes. Committee Member Present: David Agler, M.D., Dawn Berheim, Pharm.D., Perry Brown, M.D., Matthew Hyde, Pharm.D.
Idaho DUR Board Meeting Minutes Date: January 25, 2018 Time: 9am-12:00pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: David Agler, M.D. Committee Member
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Opioid Analgesics Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 11.17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the
More informationPolypharmacy. Polypharmacy. Suboptimal Prescribing in Older Adults. Kenneth Schmader, MD Professor of Medicine-Geriatrics
Polypharmacy Kenneth Schmader, MD Professor of Medicine-Geriatrics Polypharmacy Definition Causes Consequences Prevention/management Suboptimal Prescribing in Older Adults Overuse Polypharmacy Underuse
More informationFollow-up to Previous Reviews. Foster Children Prescribers (Nurse Practitioner Practice Sites)
15 January 2015 1 Follow-up to Previous Reviews Foster Children Prescribers (Nurse Practitioner Practice Sites) 2 Foster Children Prescribers (Nurse Practitioner Practice Sites) 3 Ongoing Reviews Buprenorphine
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this policy
More informationSTART, STOPP, Beers Oh My! Navigating the World of Geriatric Pharmacy
START, STOPP, Beers Oh My! Navigating the World of Geriatric Pharmacy Jessica DiLeo, PharmD Kate Murphy, PharmD OBJECTIVES Identify pharmacodynamic and pharmacokinetic parameters that may influence treatment
More informationFlorida MEDS-AD Waiver
Florida MEDS-AD Waiver 2 nd Quarter Report April 1, 2015 June 30, 2015 Demonstration Year 10 1115 Research and Demonstration Waiver #11-W-00205/4 This page intentionally left blank Table of Contents I.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lucemyra) Reference Number: CP.PMN.152 Effective Date: 07.31.18 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationHUSKY Health Benefits and Prior Authorization Requirements Grid* Behavioral Health Partnership Effective: January 1, 2012
Behavioral Health Health and Behavior Assessments (CPT 96150-96155) When Performed by Psychologists Mental Health Inpatient 100% covered under medical benefit for members with diagnoses outside the range
More informationMedication Management When Caring for Seniors at Home
Medication Management When Caring for Seniors at Home White Paper May 24, 2013 2013 Physician s Choice Private Duty http://private-duty.pchhc.com 1 Proper medication management for seniors who live at
More informationIowa Medicaid Drug Utilization Review Commission Meeting Minutes October 5, 2011
Iowa Medicaid Drug Utilization Review Commission Meeting Minutes October 5, 2011 Attendees: Commission Members Mark Graber, M.D., FACEP; Casey Clor, M.D. ; Craig Logemann, R.Ph., Pharm.D., BCPS; Sara Schutte-Schenck,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Effective Date: 04.18 Last Review Date: 04.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description
More informationTennCare Drug Utilization Review (DUR) Board Minutes
State of Tennessee Department of Finance and Administration Bureau of TennCare 310 Great Circle Road Nashville, TN 37228 TennCare Drug Utilization Review (DUR) Board Minutes September 11, 2012 In attendance:
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationClinical Policy: Olanzapine Orally Disintegrating Tablet (Zyprexa Zydis) Reference Number: CP.PMN.29 Effective Date: Last Review Date: 02.
Clinical Policy: (Zyprexa Zydis) Reference Number: CP.PMN.29 Effective Date: 08.01.15 Last Review Date: 02.19 Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory
More informationWelcome - we will begin the webinar shortly Please read the participation tips below:
Welcome - we will begin the webinar shortly Please read the participation tips below: All guest phones have been muted: Background noises, conversations, white noise etc., can be disruptive to a webinar.
More informationth Street, NW Suite 1000 Washington, DC phone fax
TO: Interested Organizations FROM: Patrick Dahill, Assistant Vice President, Accreditation & Measures Policy DATE: May 15 2017 (Updated on October 18, 2017) RE: Measures for Accreditation Scoring in 2018
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationDrug Use Evaluation: Low Dose Quetiapine
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationMonitoring Psychotropic Use Among Foster Children EMPAA
State Plans for Monitoring Psychotropic Use Among Foster Children EMPAA October 30, 2012 Child and Family Services Improvement and Innovation Act of 2011 Required Components of Psychotropic Oversight and
More informationMEASURING CARE QUALITY
MEASURING CARE QUALITY Region December 2013 For Clinical Effectiveness of Care Measures of Performance From: Healthcare Effectiveness Data and Information Set (HEDIS ) HEDIS is a set of standardized performance
More information9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)
9/9/2016 Prior Authorization Form PASSPORT HEALTH PLAN KENTUCKY MEDICAID Buprenorphine Products This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationMaryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy. Date Prescription will Start Denying at the
Maryland Medicaid Pharmacy Program & News ViewsNovember 2013 Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy The Antipsychotic Peer Review Program is Expanding!
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Analgesics, Narcotic Long Acting A. Prescriptions That Require Prior Authorization Prescriptions for Analgesics, Narcotic Long Acting
More informationliterature that drug combinations containing butalbital should not be used in treatment of chronic pain and are not appropriate for long term routine
ACTION: Original BIA p(111397) pa(192459) d: (446870) DATE: 09/16/2013 2:14 PM print date: 04/02/2019 9:58 PM 1. Limit reimbursement for sedative hypnotic agents to the following medications: zolpidem
More informationClinical Policy: Buprenorphine-Naloxone (Bunavail, Suboxone, Zubsolv) Reference Number: CP.PMN.81 Effective Date: Last Review Date: 02.
Clinical Policy: (Bunavail, Suboxone, Zubsolv) Reference Number: CP.PMN.81 Effective Date: 09.01.17 Last Review Date: 02.18 Line of Business: Medicaid See Important Reminder at the end of this policy for
More informationAugust 10, 2017 DURB Meeting Summary
Roll Call Present: Dr. Swee, Dr. Zanna (ex officio), Dr. Gooen, Dr. Marcus, Dr. Gochfeld, Dr. Moynihan, Dr. Moore, Ms. Olson, Dr. Lind (ex officio) Unable to attend: Mr. Schafer, Dr. Barberio Public Notice
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Rexulti) Reference Number: CP.PMN.68 Effective Date: 11.05.15 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More informationIntroducing ValueOptions Clinical Care Alerts
Introducing ValueOptions Clinical Care Alerts January 2013 Agenda What are Clinical Care Alerts? How does it work? What are the benefits? Questions and Answers 2 The Issue of Poor Medication Adherence
More informationGUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS
City and County of San Francisco Mayor Gavin Newsom Department of Public Health Community Behavioral Health Services 1380 Howard Street 5 th Floor San Francisco, CA 94103 GUIDELINES FOR THE USE OF PSYCHOACTIVE
More informationThere s A Pill For That (But should my patient be on it?) A Review of Tools for the Evaluation of Optimal Prescribing in Geriatric Patients
There s A Pill For That (But should my patient be on it?) A Review of Tools for the Evaluation of Optimal Prescribing in Geriatric Patients Marilyn N. Bulloch, PharmD, BCPS Assistant Clinical Professor
More informationClinical Policy: Lofexidine (Lucemyra) Reference Number: ERX.NPA.88 Effective Date:
Clinical Policy: (Lucemyra) Reference Number: ERX.NPA.88 Effective Date: 07.31.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationCOMPASS RECOVERY OPIOID REHABILITATION PROGRAM QUESTIONAIRE FOR PROSPECTIVE OPIOID REHABILITATION. Name Birthdate / /
COMPASS RECOVERY OPIOID REHABILITATION PROGRAM QUESTIONAIRE FOR PROSPECTIVE OPIOID REHABILITATION Name Birthdate / / Home phone ( ) - Cell phone ( ) - Please answer the following questions which will help
More informationCOMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK
COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK Robert L Alesiani, PharmD, CGP Chief Pharmacotherapy Officer CareKinesis, Inc. (a Tabula Rasa Healthcare Company) 2 3 4 5 Pharmacogenomics
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationEvaluation of a Medicaid Psychotropic Drug Management Program in Utah
Evaluation of a Medicaid Psychotropic Drug Management Program in Utah Dominick Esposito James M. Verdier 2008 SAMHSA/CMS Invitational Conference on Medicaid and Mental Health Service/Substance Abuse Treatment
More informationUnderstanding the Benefits and Risks
LOTRONEX and its authorized generic alosetron hydrochloride: Understanding the Benefits and Risks The LOTRONEX REMS Program Prescriber Education Slide Deck LOTRONEX is a registered trademark of Prometheus
More informationMEASURING CARE QUALITY
MEASURING CARE QUALITY Region November 2016 For Clinical Effectiveness of Care Measures of Performance From: Healthcare Effectiveness Data and Information Set (HEDIS ) HEDIS is a set of standardized performance
More informationFriend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines
Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines Program Learning Objectives At the conclusion of the activity, participants should be able to: Have a basic understanding
More informationSTOPP START Toolkit Supporting Medication Review in the Older Person
STOPP START Toolkit Supporting Medication Review in the Older Person STOPP: Screening Tool of Older People s potentially inappropriate Prescriptions START: Screening Tool to Alert doctors to Right (appropriate,
More informationFL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality
FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality April 23, 2014 Pensacola, FL Presentation Objectives To briefly describe the program and how its components
More informationThe Opioid Epidemic and How It is Impacting the Workplace. July 24, 2018
The Opioid Epidemic and How It is Impacting the Workplace July 24, 2018 In 2016 CDC reports a 300% increase in opioid prescription sales since 1999 without an overall change in reported pain National Safety
More informationSUMMARY TABLE OF MEASURE CHANGES
Summary Table of Measure 1 SUMMARY TABLE OF MEASURE CHANGES Guidelines for Physician Measurement Adult BMI Assessment Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents
More informationMaximizing Medication Safety UNIVERSITY OF HAWAII AUGUST 31, 2016
Maximizing Medication Safety UNIVERSITY OF HAWAII AUGUST 31, 2016 Adverse Drug Events (ADE s) RISK FACTORS FOR Adverse Drug Events (ADEs) 6 or more concurrent chronic conditions 12 or more doses of drugs/day
More informationNarcotics Monitoring System (NMS) Update
Narcotics Monitoring System (NMS) Update DISCLOSURE OF COMMERCIAL SUPPORT This program has received no financial or in-kind support. Potential for conflict(s) of interest: None Faculty/Presenter Disclosure
More informationPatient Review and Coordination Program
Patient Review and Coordination Program For Medical Assistance Clients Who Need Assistance In Appropriate Use of Phyllis Coolen, RN, MN Division of Healthcare Health and Recovery Administration January
More informationBlueprint for Prescriber Continuing Education Program
CDER Final 10/25/11 Blueprint for Prescriber Continuing Education Program I. Introduction: Why Prescriber Education is Important Health care professionals who prescribe extended-release (ER) and long-acting
More informationIssues for Part D Compliance
HCCA- MEDICARE PRESCRIPTION DRUG PART D COMPLIANCE CONFERENCE Issues for Part D Compliance Craig Miner, RPh, JD Division of Drug Plan Policy Babette S. Edgar, Pharm.D., MBA Division of Finance and Operations
More informationOpioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description
More informationBuprenorphine & Controlled Substance Treatment Agreement
Buprenorphine & Controlled Substance Treatment Agreement I agree to accept the following treatment contract for buprenorphine office-based opioid addiction treatment: 1. I will keep my medication in a
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
RAGWITEK (Short Ragweed Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline
More informationPOLICY AND PROCEDURE DOCUMENT NAME: Drug Recall Notification Process
PAGE: 1 of 6 SCOPE: Centene Corporate, Magnolia Health Plan Department, and Envolve Solutions. PURPOSE: To identify and notify prescribers and members affected by FDA-required or voluntary drug withdrawals
More informationGeriatric Pharmacology. Kwi Bulow, M.D. Clinical Professor of Medicine Director, Academic Geriatric Resource Center
Geriatric Pharmacology Kwi Bulow, M.D. Clinical Professor of Medicine Director, Academic Geriatric Resource Center Silver Tsunami 2010: 40 million (13%) 2030: 72 million (20%) Baby Boomers (1946-1964)
More informationDrug Use Evaluation: Short Acting Opioids (SAO)
Drug Use Evaluation: Short Acting Opioids (SAO) Summary Short acting opioid analgesics are one of the most prescribed (top 10) and highest cost (top 20) medication classes for the Oregon Fee For Service
More informationNURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE BUPRENORPHINE/NALOXONE CLINIC VISITS
Provider Name: NURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE Provider Signature: Date: BUPRENORPHINE/NALOXONE CLINIC VISITS Once stable, schedule clinic visits every 2 to 4 weeks, with refills that coincide
More information